{
    "id": 28522,
    "fullName": "CD274 rearrange",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "CD274 rearrange indicates an unspecified rearrangement of the CD274 gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 29126,
        "geneSymbol": "CD274",
        "terms": [
            "CD274",
            "B7-H",
            "B7H1",
            "hPD-L1",
            "PD-L1",
            "PDCD1L1",
            "PDCD1LG1",
            "PDL1"
        ]
    },
    "variant": "rearrange",
    "createDate": "08/01/2018",
    "updateDate": "08/01/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 14967,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with high grade ovarian carcinoma harboring a CD274 rearrangement demonstrated a complete response when treated with Keytruda (pembrolizumab) (PMID: 29351920).",
            "molecularProfile": {
                "id": 30402,
                "profileName": "CD274 rearrange"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 4001,
                "name": "ovarian carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11864,
                    "pubMedId": 29351920,
                    "title": "Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29351920"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 30402,
            "profileName": "CD274 rearrange",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}